Expression of gp100 in melanoma metastases resected before or after treatment with IFN-alpha and IL-2 by Scheibenbogen, C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23878
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Journal o f immunotherapy
19(5):375-380 © 1996 Lippincott-Raven Publishers, Philadelphia
Expression of gplOO in Melanoma Métastasés Resected Before 
or After Treatment with IFNa and IL-2
Carmen Scheibenbogen, *Imke Weyers, tD irk  Ruiter, M artina W illhauck, * Adolfo Bittinger, and
Ulrich Keilholz
Department of Internal Medicine V (Hemalology/Oncology/Rheumatoiogy), University of Heidelberg, Heidelberg, Germany; 
^Department of Pathology, University of Marburg, Germany; and f  Institute o f  Pathology, University of Nijmegen,
The Netherlands
Summary; The melanosomal protein gplOO was recently described as an antigen 
associated with tumor rejection in adoptive immunotherapy using tumor-infiltrating 
lymphocytes, In this study, we investigated whether the expression of gplOO in mela­
noma cells correlates with responsiveness to treatment with interferon-a ancl interleu­
kin-2. Using the monoclonal antibody HMB-45 recognizing gplOO, we examined 
metastatic tissue resected before therapy in 44 patients with melanoma including 9 
patients with subsequent complete or partial remission. A very heterogeneous pattern 
of gp 100-expression was found between patients, but the percentage of gp-100 positive 
cells in different metastases resected from the same patients was rather constant. This 
suggests that the gplOO expression determined in a single metastasis may be judged as 
being representative for other metastatic lesions of a patient. We found no correlation 
between expression of gplOO and responsiveness to subsequent immunotherapy. Our 
results show that the lack of gplOO before therapy is not associated with decreased 
responsiveness to subsequent cytokine treatment. Key Words: gplOO—Melanoma—  
Interleukin-2—In terfero n - a .
Several melanoma-associated antigens recognized by 
specific cytotoxic T lymphocytes could be identified in 
melanoma patients (reviewed in ref. 1). Melanoma- 
specific T cells grown from metastatic tissue or from 
peripheral blood frequently recognize two melanocyte- 
lineage specific proteins, gplOO and MART-1 (2-4). 
GplOO seems to be an important tumor rejection antigen 
for the adoptive transfer of tumor-infiltrating lympho­
cytes. Response to therapy was associated with reactivity 
of the tumor-infiltrating lymphocytes against gplOO but 
not MART-1 (4).
Little is known so far about which role these mela­
noma-associated antigens play in cytokine-induced tu­
mor regression. There are several findings suggesting 
that interleukin-2 (IL-2)-induced tumor regression in
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vivo is mediated by specific T cells. Overexpressed T~ 
cell receptor Vp chains and clonal expansion of V(3 
families were shown to be present only in responding, 
but not in progressive tumor sites from patients with 
melanoma (5-7). Although immunotherapy with inter- 
feron-ot (IFN-a) ancl IL-2 can induce profound tumor 
regression even in patients with advanced metastatic 
melanoma, many patients show progressive disease de­
spite treatment (8,9). Heterogeneity in expression o f tu­
mor antigens could account for differential responsive­
ness. The expression of gplOO in particular varies con­
siderably within the tumor and from patient to patient. 
GplOO expression can be determined using the specific 
monoclonal antibodies HMB-45 or NKI-beteb, which are 
widely used as diagnostic markers for human melanoma 
(10,11). Although >95% of primary melanoma lesions 
stain with NKI-beteb, only 80% of metastases are posi­
tive, and the percentage o f positive cells declines with 
Breslow thickness in primary melanomas ( 12).
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Considering the variable expression of gplOO, we ad­
dressed the question of whether the downregulation or 
loss of gplOO expression in melanoma métastasés influ­
ences the responsiveness to immunotherapy with IFNa/ 
IL-2. After immunotherapy, we further analyzed the ex­
pression of gplOO in regressing and progressing métas­
tasés.
MATERIALS AND METHODS 
Tissue Samples
We made an effort to collect paraffin-embedded tissue 
of melanoma metastases from 75 melanoma patients 
from 16 different pathology departments. These patients 
had been treated with IFNa and high-dose IL-2 between 
1988 and 1994 at our institution (9,13). From 46 patients, 
metastases resected before therapy were available. No 
samples could be retrieved from the remaining 29 pa­
tients for various reasons. Residual melanoma metastases 
were resected in 4 patients responding to immunotherapy 
and in 6 patients with stable disease within 12 weeks 
after the last treatment cycle (14). From two patients with 
progressive metastatic melanoma after treatment with 
immunotherapy we obtained metastases resected as pal­
liative treatment. Most of this tissue was frozen and 
stored in liquid nitrogen. The treatment protocols includ­
ing the surgical approach were approved by the Univer­
sity of Heidelberg Ethics Committee and informed con­
sent was obtained from all patients. Responses were de­
fined according to standard World Health Organization 
criteria.
Histology and Detection of gplOO by Monoclonal 
Antibody HMB-45
Sections of 4 |xm thickness were cut from paraffin- 
embedded and from frozen tissue and were stained with 
hematoxylin and eosin for routine histology. The immu- 
nohistochemical stains were performed according to a 
three-layer APAAP technique. The following primary 
antibodies were used: the polyclonal rabbit antibody 
S 100, and the monoclonal mouse antibody HMB-45 
(both purchased from Dako, Hamburg, Germany). Meta­
static lesions were examined by two independent pa­
thologists unaware of the clinical data. HMB-45 staining 
was expressed as estimated percentage of positive tumor 
cells and classified as negative, 1- 5%, 6-25%, 26-50%, 
51-75%, and 76-100% positive.
RESULTS 
Heterogeneity of gplOO Expression 
Before Treatment
Metastatic tissue resected before treatment with IFNa/ 
IL-2 from 46 patients was available. Melanoma cells 
from all but two patients showed intense reactivity with 
SI00. The two SI00-negative specimens were excluded 
from further analysis because the integrity of the material 
was uncertain. Metastatic tissue of the remaining 44 pa­
tients originated from skin (n =  6), subcutaneous tissue 
(n =  9), lymph node (n =  24), liver (n =  2), and gut 
(n — 2). Three were of unknown organ site that could 
not be determined histologically. The percentage of 
stained melanoma cells within a lesion showed a strong 
heterogeneity between different patients. Only 14 metas­
tases from 13 patients had >50% of gp 100-positive mela­
noma cells (Fig. 1; two patients are represented twice, 
because metastases from two different sites were avail­
able). In nine patients, melanoma cells were completely 
negative for gplOO, and another nine had only 5% or less 
of melanoma cells expressing gplOO. No obvious differ­
ence of gplOO expression was seen in metastases origi­
nating from different tissue.
From eight patients, more than one simultaneously re­
sected pretreatment metastasis was available, all showing 
corresponding percentages of gp 100-positive cells 
(Table 1).
cut. •  • • • •  •
SX. • •  • • •  • • # •
l.n. •
•  • • • •  • •  •  • •  • •  •
•  • •  
•
vise* •  • • •
U.O. •  • •
neg. 1-5% 6-25% 26-50% 51-75% 76-100%
FIG. t. Pattern of gplOO expression in metastatic melanoma lesions 
according to tissue origin (cut., cutaneous; s.Ci, subcutaneous; l.n., 
lymph node; vise., visceral; u.o., unknown origin). Each dot represents 
one single lesion (n = 46 from 44 patients; from 2 patients, 2 metas­
tases resected from different organ sites were included). The percent­
age of cells stained per lesion was divided into six intensity groups 
(negative, 1-5, 6-25, 26-50, 51-75, 76-100% positive melanoma 
cells).
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g p l00 EXPRESSION IN MELANOMA METASTASES
TA B LE 1. Expression o f  g p l 00  in métastasés resected  
before inteiferon-a/inter!eukin-2: comparison o f  
simultaneously resected métastasés
Patient Site gplOO
A.B. s.c. Neg.
Liver Neg.
M.R. s.c. Neg.
s.c. 1-5%
s.c. 1-5%
W.R. s.c. 1-5%
s.c. 1-5%
s.c. 1-5%
CD. Lymph node 1-5%
Lymph node 1-5%
E.M. Lymph node 51-75%
Lymph node 51-75%
Lymph node 51-75%
K.G. Cutaneous 51-75%
Cutaneous 51-75%
Lymph node 76-100%
J.F. Cutaneous 76-100%
Cutaneous 76-100%
M.M. s.c. 76-100%
s.c. 76-100%
s,c., subcutaneous.
Expression of gplOO Before Therapy and Response
to Treatment
Based on the postulated role of gplOO as a tumor 
rejection antigen, we wanted to know whether patients 
with a higher percentage of gp 100-expressing melanoma 
cells were more likely to respond to immunotherapy. We 
therefore compared the expression of gplOO in respond­
ers [complete responders/partial responders (CR/PR) 
n = 9], patients with stable disease (SD) (n =  12) and 
nonresponders [progressive disease (PD) n =  23] to sub- 
sequent therapy with IFNa/IL-2. With our semiquantita- 
tive classification, we found a clear distinction between 
positive (>25% of cells stained with HMB-45) and 
mainly negative (=s5%) melanoma lesions. Patients with 
>25% gp 100-positive melanoma cells did not respond 
better than patients with <5% positive cells (20% CR/ 
PR, 24% SD, and 56% PD, n =  25 versus 22% CR/PR, 
28% SD, and 50% PD, n =  18, respectively; Fig. 2).
Expression of gplOO in Metastases 
Resected Postimmunotherapy
We analyzed the expression of gplOO in melanoma 
metastases resected within 3 months after immuno-
T A B L E  2. Expression o f  g p l  00 in métastasés re sec te d 
after inteiferon-a/inlerleukin-2 and response ta treatment
Patient Site
Clinical
response
Regressive 
changes 
on histology
Percentage of 
gp 100-positive 
cells
S.S. s.c. PR Negative
s.c. 1-5%
S.Sch. s.c. PR + Negative
A.R. Lung PR + 6-25% "
Gut 6-25% “
A.L. Adr. gland PR
•
+ 1-5% "
A.B. Pancreas SD + Negativev.w. Gut SD + Negative
P.R. In. SD + 1-5%*
H.P. s.c. 3x SD — 1-5%
s.c. 2x — 6-25%
F.T. l.n. SD — 51-75%
M.M. s.c. SD — 51-75%
H.B. Thyr. gland PD — 26-50%
G.W. s.c. PD — 51-75%
s,c., subcutaneous; In., lymph node; PR, partial response; SD, stable 
disease; PD, progressive disease. 
a Positive only in necrotic areas.
therapy in 12 patients (4 PR, 6 SD, 2 PD; Table 2). 
Metastases from three of six patients with SD showed 
histologically marked regressive changes and fibrosis. In 
these three patients, the tumors were also found to be 
encapsulated by a fibrous wall. In six of the seven pa­
tients with either clinical PR or SD and marked regres­
sive changes on histology, either few or no gplOO- 
positive melanoma cells were found in residual lesions. 
An interesting observation was made in three of these 
patients (A.R., A.L., P.R.), all showing widely necrotic 
areas and in between areas with intact tumor structure
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FIG. 2. Pattern of gplOO expression in metastatic melanoma lesions 
according to response to subsequent treatment with interferon-a/ inter­
leukin-2, Each dot represents a single lesion from 44 patients [complete 
responders (CR) n = 2; partial responders (PR) n = 7; stable disease 
(SD) n =  12; PD n =  23]. The percentage of cells stained per lesion 
was divided into six intensity groups (negative, 1-5, 6-25, 26-50» 
51-75, 76-100% positive melanoma cells).
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TA BLE 3. Expression o f  gp 100 in metastases resected 
before and after interferon-a and interleukin-2: comparison
in individual patients
Patient
Clinical
response
Regressive 
changes 
on histology She
Percentage of 
gpl 00-positive 
cells
S.S. s.c. (pre) 26-50%
PR + l.n. (post) Neg.
PR s.c. (post) 1-5%
P.R. l.n. (pre) 76-100%
SD + I.n. (post) 1-5%
S. Sch. s.c. (pre) Neg.
PR + s.c. (post) Neg.
A.B. Liver (pre) Neg.
PR + Pancr, (post) Neg.
V.W. Gut (pre) Neg.
SD + Gut (post) Neg.
F.T. In. (pre) 26-50%
SD — l.n. (post) 51-75%
M.M. s.c. (pre) 76-100%
SD — s.c. (post) 51-75%
H.B. I.n. (pre) 26-50%
PD — Thyr. (post) 26-50%
s.c., subcutaneous; I.n., lymph node; thyr., thyroid gland; PR, partial 
response; SD, stable disease; PD, progressive disease.
(Fig, 3). Some remaining cells in these necrotic areas 
were positive for gplOO, whereas the tumor cells in areas 
with intact tumor structure were gplOO negative. Three 
patients with SD and 2 patients with PD showed no signs 
of tumor regression on histology. In four of these five 
patients, metastases with >25% positive melanoma cells 
were found.
Comparison of gplOO Expression 
Pre- and Postimmunotherapy
From eight patients, metastases resected before and 
after therapy were available (Table 3). In two patients, 
S.S. and P.R., who had responded to therapy, in the 
residual lesions <5% of the remaining cells expressed 
gplOO. The histology in patient P.R., who had clinically 
a SD, revealed a tumor with extensive necrosis and only 
some intact tumor cells at the rim encapsulated by fi­
brous tissue. Only a few remaining cells in the widely 
necrotic areas were positive for gplOO (Fig. 3). In the 
metastases resected from these two patients from the 
same anatomic area before therapy, >25 and >75% of 
melanoma cells, respectively, were gplOO positive. In 
three responding patients, metastases resected before and 
after immunotherapy were negative for gplOO. The me­
tastases of two patients (F.T. and M.M.) with clinical SD 
and no evidence of tumor regression on histology and of 
one patient (H.B.) with PD all contained >25% gp 100- 
positive melanoma cells, and a similar percentage of
positive melanoma cells was seen in the metastases be­
fore therapy.
DISCUSSION
We found a very heterogeneous pattern in the percent­
age of gp 100-expressing melanoma cells in the metasta­
ses from 44 patients resected before immunotherapy. 
This is in accordance with the findings reported in an 
earlier study from the EORTC Melanoma Cooperative 
Group, in which a similar distribution in the percentage 
of gp l00-positive melanoma cells was found in metas­
tases (12). In this former study, the monoclonal antibody 
NKI-beteb was used, which recognizes a different epit­
ope of gplOO, but shows the same reactivity as HMB-45 
in melanoma metastases (11,15). In contrast to this in­
terindividual heterogeneity, we found that different 
melanoma metastases originating from the same patient 
showed a corresponding pattern in the percentage of 
gp 100-positive tumor cells. We also could not observe a 
different pattern in cutaneous, subcutaneous, or lymph 
node metastases. This suggests that the gplOO expression 
determined in a single metastasis may be judged as being 
representative for other metastatic lesions of a patient. 
This cannot be concluded for visceral metastases from 
our data, because we examined only four metastases, and 
three of them were gplOO negative.
The main question of this study was whether hetero­
geneity in gplOO expression correlates with responsive­
ness to immunotherapy with IFNa/IL-2. Patients with 
gpl00-negative or ^5% positive tumor cells, however, 
responded as well as patients with >25% positive cells. 
Therefore, additional or other melanoma-associated an­
tigens than gplOO may play a role in cytokine-mediated 
tumor destruction and could influence the differentia] 
responsiveness. A heterogeneity of expression of both 
MART-1 and tyrosinase-related protein in metastatic 
melanoma was shown recently (16,17). Also the loss of 
HLA alleles, of functional 32-microglobulin and differ­
ential expression of adhesion antigens were shown to 
occur in individual patients during tumor progression, 
which could lead to escape from T-cell recognition (18- 
20).
Our findings in the metastases resected after immuno­
therapy are only descriptive because of the low number 
of patients with metastases available before and after 
immunotherapy. We found that the melanoma cells in 
most of the regressing lesions after therapy expressed 
either little or no gplOO. In two of the patients pretreat­
ment metastases were available, in which at least 25% of 
tumor cells were gpl00~positive. It is unclear whether 
this loss of gplOO is a consequence of dedifferentiation
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